Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs
© Koizumi and Iwami; licensee BioMed Central Ltd. 2014
Received: 7 June 2014
Accepted: 15 September 2014
Published: 25 September 2014
In the current era of antiviral drug therapy, combining multiple drugs is a primary approach for improving antiviral effects, reducing the doses of individual drugs, relieving the side effects of strong antiviral drugs, and preventing the emergence of drug-resistant viruses. Although a variety of new drugs have been developed for HIV, HCV and influenza virus, the optimal combinations of multiple drugs are incompletely understood. To optimize the benefits of multi-drugs combinations, we must investigate the interactions between the combined drugs and their target viruses. Mathematical models of viral infection dynamics provide an ideal tool for this purpose. Additionally, whether drug combinations computed by these models are synergistic can be assessed by two prominent drug combination theories, Loewe additivity and Bliss independence. By combining the mathematical modeling of virus dynamics with drug combination theories, we could show the principles by which drug combinations yield a synergistic effect. Here, we describe the theoretical aspects of multi-drugs therapy and discuss their application to antiviral research.
KeywordsAntiviral therapy Mathematical modeling Drug combination theory Virus dynamics
Several landmark mathematical modeling studies of anti-retroviral therapy were reported in 1995[1–4]. Thereafter, mathematical modeling has provided quantitative insights into antiviral drugs targeting HIV[5–13], HCV[14–18], HBV[19, 20] and influenza virus[21, 22]. These studies have elucidated the key steps of viral replication cycles and viral infection dynamics, such as the half-life of viruses and how viruses replicate in cells (reviewed in[23–27]). Although mathematical viral models could also search for drug combinations that improve antiviral effects and prevent the emergence of drug-resistant viruses, this potential of viral modeling has yet to be properly explored. Multi-drug administration is a standard treatment for HIV and HCV infection, and is also required in HBV and influenza. The established combination drug therapy for HIV, known as highly active anti-retroviral therapy (HAART), remains prohibitively expensive in developing countries. Additionally, HIV patients receiving long-term HAART may experience severe side effects such as lipodystrophy, hepatotoxicity, renal dysfunction, peripheral neuropathy and cardiovascular diseases (reviewed in). By optimizing drug combinations, we could reduce the doses of individual drugs, thereby lowering the cost of treatment, reducing side effects, enhancing the antiviral effects and reducing the risk of drug-resistant viruses.
To accelerate the above benefits of drug combinations, we need to know whether or not a drug combination exerts a synergistic effect (reviewed in[29, 30]). A non-synergistic drug combination requires a larger than expected dose to achieve a regular antiviral effect. Although multi-drug therapy is standard practice, the complexity of the combined drugs’ responses is improperly understood, and rendered counter-intuitive by drug absorption, distribution, metabolism, and excretion through drug transporters. To overcome these difficulties, comprehensive trials (or experiments) of various combinations and doses of drugs have been required. The combined effect has been investigated by empirical methods such as Loewe additivity[29, 31] and Bliss independence[29, 32]. Both theories have evolved from pharmacological research, and are used to classify combination effects as synergistic, additive or antagonistic[29, 33, 34]. These empirical frameworks have become widely accepted in pharmacology and have provided quantitative insight into drug combinations. However, because their underlying mechanics are unknown, the frameworks cannot provide reasons for a given combination effect (e.g. why is this drug combination additive, whereas that combination is antagonistic?). Showing the mechanisms of drug combination effects is expected to remarkably advance the development of multicomponent therapeutics. Thus, in addition to judging drug combination effects, knowledge of the mechanism is crucial to fundamental antiviral research.
Here we discuss two primary concepts of drug combination theory: Loewe additivity and Bliss independence. We apply these models to viral replication in a host cell, and discuss their utility for understanding two-drug interactions and viral dynamics. Finally, we discuss how drug combination theory might be applied to cancer chemotherapies and antiviral therapies. Combining mathematical models of viral replication with drug combination theory, we can establish an efficient framework for optimizing drug combinations.
Basic drug combination theory: Loewe additivity
where the right hand side of Eq. (2) is identical to the left side of Eq. (1). When CI < 1, the relationship is synergetic, when CI = 1, it is additive, and when CI > 1, it is antagonistic. For example, suppose that 4 μM of drug A and 5 μM of drug B exert the same effect as a combination of 1 μM of A and 2 μM of B. Substituting these concentrations into Eq. (2), we obtain CI = 0.65 (=1/4 + 2/5 < 1), implying that the drug combination is synergistic. Note that the CI does not express the extent of synergy or antagonism; it is merely a criterion that separates the two behaviors without quantifying them.
Numerically solving Eq. (4) for E, we can predict the additive effect at any drug concentrations and[35, 36]. The following section explains an example of applying Loewe additivity to estimate rational drug combinations and optimal doses.
Application of Loewe additivity for estimating rational drug combinations and optimal doses
The alternative drug combination theory: Bliss independence
If the combined effect of the single drug doses is consistent with Eq. (6), this drug combination is evaluated as additive according to the Bliss independence measure. For instance, suppose that drugs A and B exhibit 50% and 60% inhibition, respectively. The Bliss independence predicts that drugs A and B will exert a combined inhibitory effect of 80%, calculated as P AB = 0.5 + 0.6 - 0.5 × 0.6 = 0.8.
Unlike the Loewe additivity, the Bliss independence can evaluate the effect of a drug combination without requiring dose–response curves of the single drugs. If we attempt to assess a drug combination by the Loewe additivity, we must measure the effects at several single doses for constructing the dose–response curve. In contrast, the Bliss independence can assess the effects of a drug combination from a single point. Thus, the Bliss independence is useful if experimental data are limited. Additionally, in specific cases, the Bliss independence and Loewe additivity can be rendered equivalent using the Hill function Eq. (3). The following section explains an example of applying Bliss independence to quantifying the antiviral effects of intrinsic factors on HIV replication.
Quantifying the antiviral effects of APOBEC3G on HIV replication by Bliss independence
where x is the expression level of APOBEC3G, h RT and h Mu are Hill coefficients, and and are the expression levels required to achieve 50% inhibition by reverse transcription inhibition and C-to-U mutation, respectively. We estimated 4 parameters (h RT , h Mu ,, and) by fitting to experimental data of WT and mutated APOBEC3G (Figure 2B). Thus, the anti-HIV effect of C-to-U mutation by APOBEC3G can be quantitatively estimated by a Bliss independence-based modeling approach.
Potential applications of drug combination theory
The Loewe additivity and Bliss independence form the basis of sophisticated protocols for assessing drug combinations, especially in cancer-targeted chemotherapy[33, 34]. Research on biological network systems, as well as the biochemical characteristics of drugs, has also unraveled the mechanisms by which drug combinations produce synergistic effects (reviewed in[41, 43–45]). Such research is important because (1) it facilitates rational drug discovery and (2) it predicts unknown connectivities in biological networks. Regarding the first point, the effects of a developing drug combined with conventional drugs are maximized by investigating biological networks, and rational drug targets are decided. For example, using computational modeling of cancer signaling networks and animal experiments, Kirouac et al. identified the optimal inhibitor combination for suppressing the growth of ERBB2-amplified breast cancer. They adopted Bliss independence as a synergy criterion. Supplementing this computational approach with experimental data is useful for developing theoretically effective novel drugs. Regarding point (2), the biological networks of signaling pathways constructed by various components can be predicted from the dose–response shapes of drug combinations (reviewed in). Lehar et al. used several drug combination criteria, including Loewe additivity and Bliss independence, to connect biological components from the results of cellular responses to chemical combinations. This approach assumes that the dose–response shape of a drug combination depends on how drug targets are connected in a biological system.
We have reviewed two major drug combination theories, Loewe additivity and Bliss independence, and discussed how combining these theories with mathematical modeling of viral dynamics might assist antiviral drug therapy. In addition, we have proposed an efficient framework for optimizing drug combinations and quantifying the anti-viral effect. Based on previous studies of computational virology, the integration of drug combination theory and dynamic modeling is a new approach with great potential for showing viral responses to drug combinations, and accelerating novel antiviral drug discovery.
This research is partly supported by a Grants-in-Aid for Young Scientists B25800092 (to S.I.) from the Japan Society for the Promotion of Science (JSPS); the Kyushu University Interdisciplinary Programs in Education and Projects in Research Development (to S.I.); the Aihara Innovative Mathematical Modeling Project, JSPS through the “Funding Program for World-Leading Innovative R & D on Science and Technology (FIRST program)”, initiated by Council for Science and Technology Policy (to S.I.).
- Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995, 373: 123-126. 10.1038/373123a0.View ArticlePubMedGoogle Scholar
- Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH: Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995, 373: 117-122. 10.1038/373117a0.View ArticlePubMedGoogle Scholar
- Nowak MA, Bonhoeffer S, Loveday C, Balfe P, Semple M, Kaye S, Tenant-Flowers M, Tedder R: HIV results in the frame. Results confirmed. Nature. 1995, 375: 193-View ArticlePubMedGoogle Scholar
- Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995, 267: 483-489. 10.1126/science.7824947.View ArticlePubMedGoogle Scholar
- Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996, 271: 1582-1586. 10.1126/science.271.5255.1582.View ArticlePubMedGoogle Scholar
- Wein LM, Zenios SA, Nowak MA: Dynamic multidrug therapies for HIV: a control theoretic approach. J Theor Biol. 1997, 185: 15-29. 10.1006/jtbi.1996.0253.View ArticlePubMedGoogle Scholar
- Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997, 387: 188-191. 10.1038/387188a0.View ArticlePubMedGoogle Scholar
- Notermans DW, Goudsmit J, Danner SA, de Wolf F, Perelson AS, Mittler J: Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS. 1998, 12: 1483-1490. 10.1097/00002030-199812000-00010.View ArticlePubMedGoogle Scholar
- Wein LM, D’Amato RM, Perelson AS: Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol. 1998, 192: 81-98. 10.1006/jtbi.1997.0622.View ArticlePubMedGoogle Scholar
- Di Mascio M, Markowitz M, Louie M, Hogan C, Hurley A, Chung C, Ho DD, Perelson AS: Viral blip dynamics during highly active antiretroviral therapy. J Virol. 2003, 77: 12165-12172. 10.1128/JVI.77.22.12165-12172.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF: Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A. 2008, 105: 4832-4837. 10.1073/pnas.0711372105.PubMed CentralView ArticlePubMedGoogle Scholar
- Shen L, Rabi SA, Sedaghat AR, Shan L, Lai J, Xing S, Siliciano RF: A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Sci Transl Med. 2011, 3: 91ra63-PubMed CentralView ArticlePubMedGoogle Scholar
- Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA: Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med. 2012, 18: 1378-1385. 10.1038/nm.2892.PubMed CentralView ArticlePubMedGoogle Scholar
- Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK: Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology. 1998, 28: 245-252. 10.1002/hep.510280132.View ArticlePubMedGoogle Scholar
- Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998, 282: 103-107.View ArticlePubMedGoogle Scholar
- Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS: Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004, 432: 922-924. 10.1038/nature03153.View ArticlePubMedGoogle Scholar
- Dahari H, Ribeiro RM, Perelson AS: Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology. 2007, 46: 16-21. 10.1002/hep.21657.View ArticlePubMedGoogle Scholar
- Dahari H, Sainz B, Perelson AS, Uprichard SL: Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. J Virol. 2009, 83: 6383-6390. 10.1128/JVI.02612-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Lewin SR, Ribeiro RM, Walters T, Lau GK, Bowden S, Locarnini S, Perelson AS: Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology. 2001, 34: 1012-1020. 10.1053/jhep.2001.28509.View ArticlePubMedGoogle Scholar
- Dahari H, Shudo E, Ribeiro RM, Perelson AS: Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology. 2009, 49: 32-38. 10.1002/hep.22586.PubMed CentralView ArticlePubMedGoogle Scholar
- Beauchemin CAA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, Ribeiro RM, Perelson AS: Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol. 2008, 254: 439-451. 10.1016/j.jtbi.2008.05.031.PubMed CentralView ArticlePubMedGoogle Scholar
- Dobrovolny HM, Gieschke R, Davies BE, Jumbe NL, Beauchemin CAA: Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study. J Theor Biol. 2011, 269: 234-244. 10.1016/j.jtbi.2010.10.017.View ArticlePubMedGoogle Scholar
- Nowak M, May RM: Virus Dynamics: Mathematical Principles of Immunology and Virology. 2001, USA: Oxford University Press, 256-Google Scholar
- Perelson AS: Modelling viral and immune system dynamics. Nat Rev Immunol. 2002, 2: 28-36. 10.1038/nri700.View ArticlePubMedGoogle Scholar
- Rong L, Perelson AS: Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol. 2009, 260: 308-331. 10.1016/j.jtbi.2009.06.011.PubMed CentralView ArticlePubMedGoogle Scholar
- Guedj J, Rong L, Dahari H, Perelson AS: A perspective on modelling hepatitis C virus infection. J Viral Hepat. 2010, 17: 825-833. 10.1111/j.1365-2893.2010.01348.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Chatterjee A, Guedj J, Perelson AS: Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?. Antivir Ther. 2012, 17: 1171-1182. 10.3851/IMP2428.PubMed CentralView ArticlePubMedGoogle Scholar
- Hawkins T: Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Res. 2010, 85: 201-209. 10.1016/j.antiviral.2009.10.016.View ArticlePubMedGoogle Scholar
- Greco WR, Bravo G, Parsons JC: The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995, 47: 331-385.PubMedGoogle Scholar
- Tallarida RJ: Drug synergism: its detection and applications. J Pharmacol Exp Ther. 2001, 298: 865-872.PubMedGoogle Scholar
- Loewe S: The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953, 3: 285-290.PubMedGoogle Scholar
- Bliss CI: The toxicity of poisons applied jointly. Ann Appl Biol. 1939, 26: 585-615. 10.1111/j.1744-7348.1939.tb06990.x.View ArticleGoogle Scholar
- Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006, 58: 621-681. 10.1124/pr.58.3.10.View ArticlePubMedGoogle Scholar
- Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70: 440-446. 10.1158/0008-5472.CAN-09-1947.View ArticlePubMedGoogle Scholar
- Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55.View ArticlePubMedGoogle Scholar
- Martinez-Irujo JJ, Villahermosa ML, Alberdi E, Santiago E: A checkerboard method to evaluate interactions between drugs. Biochem Pharmacol. 1996, 51: 635-644. 10.1016/S0006-2952(95)02230-9.View ArticlePubMedGoogle Scholar
- Dahari H, Ribeiro RM, Rice CM, Perelson AS: Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J Virol. 2007, 81: 750-760. 10.1128/JVI.01304-06.PubMed CentralView ArticlePubMedGoogle Scholar
- McLean AK, Luciani F, Tanaka MM: Trade-offs in resource allocation in the intracellular life-cycle of hepatitis C virus. J Theor Biol. 2010, 267: 565-572. 10.1016/j.jtbi.2010.09.031.View ArticlePubMedGoogle Scholar
- Nakabayashi J: A compartmentalization model of hepatitis C virus replication: an appropriate distribution of HCV RNA for the effective replication. J Theor Biol. 2012, 300: 110-117.View ArticlePubMedGoogle Scholar
- Binder M, Sulaimanov N, Clausznitzer D, Schulze M, Hüber CM, Lenz SM, Schlöder JP, Trippler M, Bartenschlager R, Lohmann V, Kaderali L: Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle. PLoS Pathog. 2013, 9: e1003561-10.1371/journal.ppat.1003561.PubMed CentralView ArticlePubMedGoogle Scholar
- Jonker DM, Visser SA, van der Graaf PH, Voskuyl RA, Danhof M: Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther. 2005, 106: 1-10.1016/j.pharmthera.2004.10.014.View ArticlePubMedGoogle Scholar
- Kobayashi T, Koizumi Y, Takeuchi JS, Misawa N, Kimura Y, Morita S, Aihara K, Koyanagi Y, Iwami S, Sato K: Quantification of Deaminase Activity-Dependent and -Independent Restriction of HIV-1 Replication Mediated by APOBEC3F and APOBEC3G through Experimental-Mathematical Investigation. J Virol. 2014, 88: 5881-5887. 10.1128/JVI.00062-14.PubMed CentralView ArticlePubMedGoogle Scholar
- Keith CT, Borisy AA, Stockwell BR: Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. 2005, 4: 71-78. 10.1038/nrd1609.View ArticlePubMedGoogle Scholar
- Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK: Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol. 2006, 2: 458-466. 10.1038/nchembio817.View ArticlePubMedGoogle Scholar
- Zimmermann GR, Lehár J, Keith CT: Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007, 12: 34-42. 10.1016/j.drudis.2006.11.008.View ArticlePubMedGoogle Scholar
- Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, Pace E, McDonagh CF, Nielsen UB, Onsum MD: Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal. 2013, 6: ra68-View ArticlePubMedGoogle Scholar
- Lehár J, Stockwell BR, Giaever G, Nislow C: Combination chemical genetics. Nat Chem Biol. 2008, 4: 674-681. 10.1038/nchembio.120.PubMed CentralView ArticlePubMedGoogle Scholar
- Lehár J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, Short GF, Giusti LC, Nolan GP, Magid OA, Lee MS, Borisy AA, Stockwell BR, Keith CT: Chemical combination effects predict connectivity in biological systems. Mol Syst Biol. 2007, 3: 80-PubMed CentralView ArticlePubMedGoogle Scholar
- Owens CM, Mawhinney C, Grenier JM, Altmeyer R, Lee MS, Borisy AA, Lehár J, Johansen LM: Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication. Mol Syst Biol. 2010, 6: 375-PubMed CentralView ArticlePubMedGoogle Scholar
- Guedj J, Perelson AS: Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology. 2011, 53: 1801-1808. 10.1002/hep.24272.PubMed CentralView ArticlePubMedGoogle Scholar
- Guedj J, Neumann AU: Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J Theor Biol. 2010, 267: 330-340. 10.1016/j.jtbi.2010.08.036.View ArticlePubMedGoogle Scholar
- Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS: Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013, 110: 3991-3996. 10.1073/pnas.1203110110.PubMed CentralView ArticlePubMedGoogle Scholar
- Rong L, Guedj J, Dahari H, Coffield DJ, Levi M, Smith P, Perelson AS: Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLoS Comput Biol. 2013, 9: e1002959-10.1371/journal.pcbi.1002959.PubMed CentralView ArticlePubMedGoogle Scholar
- Rong L, Perelson AS: Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents. Math Biosci. 2013, 245: 22-30. 10.1016/j.mbs.2013.04.012.PubMed CentralView ArticlePubMedGoogle Scholar
- Rong L, Dahari H, Ribeiro RM, Perelson AS: Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med. 2010, 2: 30ra32-PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.